Jim Simons Annexon, Inc. Transaction History

Renaissance Technologies LLC

$56.7 Billion
Q2 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Annexon, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 584,200 shares of ANNX stock, worth $4.07 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

584,200

Previous 671,200 12.96%

Holding current value

$4.07 Million

Previous $4.81 Million 40.54%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$4.33 - $6.79 $376,710 - $590,730	-87,000 Reduced 12.96%	584,200 $2.86 Million
Q1 2024 May 13, 2024	BUY	$4.03 - $7.81 $753,610 - $1.46 Million	187,000 Added 38.62%	671,200 $4.81 Million
Q4 2023 Feb 13, 2024	SELL	$1.63 - $4.63 $125,689 - $357,019	-77,110 Reduced 13.74%	484,200 $2.2 Million
Q3 2023 Nov 14, 2023	BUY	$2.13 - $3.84 $296,304 - $534,182	139,110 Added 32.95%	561,310 $1.33 Million
Q2 2023 Aug 11, 2023	BUY	$2.1 - $6.37 $136,710 - $414,687	65,100 Added 18.23%	422,200 $1.49 Million
Q1 2023 May 12, 2023	BUY	$3.74 - $7.46 $175,780 - $350,620	47,000 Added 15.16%	357,100 $1.38 Million
Q4 2022 Feb 13, 2023	SELL	$4.56 - $6.61 $91,655 - $132,861	-20,100 Reduced 6.09%	310,100 $1.6 Million
Q3 2022 Nov 14, 2022	SELL	$3.75 - $6.63 $111,375 - $196,911	-29,700 Reduced 8.25%	330,200 $2.04 Million
Q2 2022 Aug 12, 2022	SELL	$2.11 - $4.06 $499,287 - $960,713	-236,629 Reduced 39.67%	359,900 $1.36 Million
Q1 2022 May 13, 2022	BUY	$2.73 - $11.94 $1.35 Million - $5.92 Million	495,629 Added 491.21%	596,529 $1.63 Million
Q4 2021 Feb 11, 2022	BUY	$11.49 - $22.0 $1.16 Million - $2.22 Million	100,900 New	100,900 $1.16 Million

Others Institutions Holding ANNX

# of Institutions

158

Shares Held

101M

Call Options Held

3.61M

Put Options Held

1.08M

View Full List

About Annexon, Inc.

Ticker ANNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,617,700
Market Cap $332M
Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...

More about ANNX

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account